Product Pipeline

Xenon is focused on advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression

Our lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD).

Our early-stage work leverages our deep ion channel expertise to develop promising drug candidates that target sodium and potassium channels.

Download Pipeline in PDF format

Early-Stage Programs
Azetukalner (FOS)
Azetukalner (PGTCS)
Azetukalner (MDD)
Azetukalner (BPD)
Partnered Programs

Medical Affairs

Learn more about our ongoing clinical trials

View Medical Affairs

Publications

See publications related to our clinical development candidates

View Publications

Partners

Find out more about collaborating with Xenon

View Partners